NewsBenzingaCerenome公布了其正在进行的ReSPECT-LM研究中REYOBIQ重复脑室内给药的中期数据;尚未报告剂量限制性毒性或导致治疗中止的不良事件 Cerenome公布了其正在进行的ReSPECT-LM研究中REYOBIQ重复脑室内给药的中期数据;尚未报告剂量限制性毒性或导致治疗中止的不良事件 Benzinga 2026.11.16 12:32 (GMT+0) Open on Benzinga Other news NRX Pharmaceuticals Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $1.159M Miss $1.300M Estimate HUYA Q3 Adj. EPS $0.03 Up From $0.02 YoY, Sales $261.441M Up From $237.147M YoY Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’ Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk Top Wall Street Forecasters Revamp Energizer Expectations Ahead Of Q4 Earnings
Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’
Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL
Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk